Opendata, web and dolomites


Novel ultrasensitive detection device for early Sepsis diagnosis

Total Cost €


EC-Contrib. €






Project "IVD4Sepsis" data sheet

The following table provides information about the project.


Organization address
postcode: 15707
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MECWINS SA ES (SANTIAGO DE COMPOSTELA) coordinator 50˙000.00


 Project objective

More than 27 M people per year develop sepsis, which has been catalogued as a Global health problem & priority. Sepsis kills more people than AIDs, prostate and breast cancer combined globally, and it lack of appropriate diagnostic tools. Moreover it has been demonstrated that early detection during the first hours is crucial for survival. Mecwins has developed the AVAC Technology prototype, an ultrasensitive detection equipment for early detection of sepsis, with: i) sensitivity a million times higher than current levels in clinical practice, ii) requiring smaller biological sample for the test, iii) multiplexing capability 30 biomarkers per analysis, iv) less diagnosis time ≤20 min, v) scalable solution - reference technology applicable to a wide range of other clinical applications (oncology, cardiovascular, autoimmune diseases, etc.). The unique value proposition of AVAC Technology is based on the early, accurate and fast diagnosis of sepsis and its competitive price (30€ per test versus 150€ per test with PCR-Roche) compared to current techniques (PCR & ELISA). Sepsis market is included on the infectious market and it was worth 278 M€ in 2015. Some estimations claim that it will grow until 717 M€ in 2021. Mecwins foresees to reach 25% of the total market by 2027 IVD4Sepsis through a double one-off revenue business model, and expecting a turnover accounting for almost 42,5 M€ by 2025.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IVD4SEPSIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IVD4SEPSIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More